Vaccines Articles
According to a cohort study using target trial emulation, older adults at higher risk for dementia are less likely to have a dementia diagnosis if they received a herpes zoster (shingles) vaccine.
A study has found pediatric flu vaccines significantly reduce the number of childhood cases of influenza.
A study has found the combination of a vaccine and a drug, which both harness the immune system to attack cancer cells, is successful in cutting the risk of skin cancer recurrence and death by 49 percent.
A recent study in Taiwan that examined the vaccine effectiveness (VE) against moderate to severe COVID-19 infection in children aged 6 to 11 years found the Pfizer/BioNTech BNT162b2 VE was 69.9 percent and the Moderna mRNA-1273 VE was 75.5 percent during Omicron BA.2/BA.5 predominance in 2022.
According to multiple large observational studies, the risk of dementia is associated with eight routine adult vaccines: the shingles, respiratory syncytial virus, influenza, DTP (diphtheria, tetanus and pertussis), pneumococcal, hepatitis A, hepatitis B and typhoid vaccines.
A potentially effective mucosal vaccine platform has been developed to encourage broad, protective immunity against multiple influenza virus infections.
A new study shows that influenza vaccination may help protect against heart attack and stroke even when it does not prevent people from getting the flu.
Researchers have found that adults 65 and older who received a high-dose influenza vaccine had a significantly lower risk of developing Alzheimer’s disease compared to those who received the standard dose.
The U.S. Food and Drug Administration has expanded the approved age indication of AREXVY to adults aged 18 to 49 years at increased risk for lower respiratory tract disease caused by RSV.
Researchers have discovered why the unusual side effect of a blood clot that impacted some recipients of the Oxford/AstraZeneca and Johnson & Johnson COVID-19 vaccines occurred.
Stanford Medicine researchers have invented a new vaccine that protects mice from respiratory viruses, bacteria and allergens, which is the closest yet to a universal vaccine.
A vaccine candidate called GBP511 that builds upon a self-assembling nanoparticle technology has begun human clinical testing in Australia.